Hims & Hers Health reported Q2 revenue of $753.21 million, up 38% year-over-year, beating estimates. However, the company posted a wider-than-expected GAAP loss of $0.37 per share due to declining gross margins and rising operating expenses. Legal troubles surfaced as the FTC and others filed a lawsuit alleging data sharing and deceptive practices, prompting a securities investigation. Despite these issues, the company raised its 2026 revenue guidance but lowered its adjusted EBITDA forecast, reflecting ongoing profitability pressures from expansion efforts.
Hims & Hers Health reported a 38% revenue increase in Q2 to $753.2 million and raised its full-year revenue forecast to $3.1–$3.3 billion. Despite a six-point drop in gross margin to 64%, the company is evolving into a distribution platform for brand...
Berger Montague PC is investigating Hims & Hers Health, Inc. for possible breaches of fiduciary duties including improper sharing of private health data with advertisers, deceptive billing practices, and making subscription cancellations difficult. T...
Anthropic will embed persistent watermarks and provenance metadata in all AI-generated content from its Claude models in the EU starting August 2, complying with the EU AI Act for transparency. Sea Limited's stock rallied after beating Q2 revenue exp...
Hims & Hers Health reported a 38% year-over-year revenue increase to $753.2 million in Q2 2026, surpassing analyst expectations of $699 million. However, the company posted a larger-than-expected loss of $0.37 per share, driven by restructuring costs...
Hims & Hers Health, Inc. reported a second-quarter 2026 earnings per share (EPS) loss of $0.10, missing the expected loss of $0.05. However, the company exceeded revenue expectations with $753.21 million, above the $698.89 million estimate, driven by...
